Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast...
Breast CancerMetastasis1 moreThe primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary...
Subfoveal Choroidal Neovascularization (CNV)Secondary to Age-related Macular Degeneration (AMD)This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic...
CancerNeoplasm MetastasisThis study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.
Breast CancerNeoplasm MetastasisTolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple...
Secondary Progressive Multiple SclerosisA present there is no safe treatment for reducing rate at which disability worsens in people with secondary progressive multiple sclerosis. Recent research has suggested the possibility that drugs that act by blocking the entry of sodium into nerve cells can protect nerve fibres in the brain and spinal cord. In this trial, the investigators will test whether one such drug, called lamotrigine, can prevent damage to nerve fibres and reduce the rate at which MS worsens. The period of treatment in the trial will run for 2 years.
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
MelanomaNeoplasm MetastasisMelanoma with a tumor thickness >= 1.5mm without clinically detectable nodes represents an increasing population with relapse rate of more than 50%. Adjuvant therapy with low doses of IFN alpha can provide a benefit in this group. However, the impact of low dose IFN alpha is not sustained after the treatment period. A longer treatment may prolong the benefit and thus have a more clear-cut impact on disease-free and overall survival. The tolerance and the impact on quality of life are limiting factors in a group of patients whose individual course is not necessarily poor. PegIntron may be better tolerated than instant release interferon, and thus make this treatment more acceptable in terms of toxicity and quality of life. Thus treatment schedule with PegIntron is not expected to increase the cost of standard care significantly.
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Non-small Cell Lung Cancer (NSCLC)Lung Cancer1 moreThis trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and overall survival (OS).
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients...
PainThis study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
Metastatic Gastric Cancer FFCD 03-07
Stomach CancerNeoplasm MetastasisThe purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
Breast CancerNeoplasm MetastasisThis is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.